The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

NCT00133731 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

947

Enrollment

INDUSTRY

Sponsor class

Conditions

Angioplasty, Transluminal, Percutaneous Coronary

Interventions

DRUG: Otamixaban (XRP0673)
DRUG: Unfractionated Heparin
PROCEDURE: Percutaneous Coronary Intervention

Sponsor

Sanofi